Clare J Twist1, Arlene Naranjo2, Mary Lou Schmidt3, Sheena C Tenney2, Susan L Cohn4, Holly J Meany5, Peter Mattei6, E Stanton Adkins7, Hiroyuki Shimada8, Wendy B London9, Julie R Park10, Katherine K Matthay11, John M Maris6,12. 1. 1 Roswell Park Cancer Institute, Buffalo, NY. 2. 2 University of Florida, Gainesville, FL. 3. 3 University of Illinois at Chicago College of Medicine, Chicago, IL. 4. 4 University of Chicago, Chicago, IL. 5. 5 Children's National Medical Center, Washington, DC. 6. 6 Children's Hospital of Philadelphia, Philadelphia, PA. 7. 7 Palmetto Health USC Medical Group, Columbia, SC. 8. 8 Children's Hospital Los Angeles, Los Angeles, CA. 9. 9 Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA. 10. 10 Seattle Children's Hospital, Seattle, WA. 11. 11 University of California San Francisco School of Medicine and UCSF Benioff Children's Hospital, San Francisco, CA. 12. 12 Perelman School of Medicine, Philadelphia, PA.
Abstract
PURPOSE:Infants with stage 4S neuroblastoma usually have favorable outcomes with observation or minimal chemotherapy. However, young infants with symptoms secondary to massive hepatomegaly or with unfavorable tumor biology are at high risk of death. Our aim was to improve outcomes for patients with symptomatic and/or unfavorable biology 4S neuroblastoma with a uniform treatment approach using a biology- and response-based algorithm. PATIENTS AND METHODS: The subset of patients with 4S disease with MYCN-not amplified tumors with impaired or impending organ dysfunction, or with unfavorable histology and/or diploid DNA index, were eligible. Patients were assigned to receive two, four, or eight cycles of chemotherapy on the basis of histology, diploid DNA index, chromosome arm 1p or 11q loss of heterozygosity (LOH) status, and symptoms. RESULTS:Forty-nine eligible patients were enrolled: 41 were symptomatic and 28 had unfavorable biology. Seventeen patients (symptomatic, favorable biology) were assigned two cycles, 21 patients (any unfavorable biologic feature without 1p or 11q LOH) were assigned four cycles, and 11 patients (unfavorable biology including 1p and/or 11q LOH [n = 7] or symptomatic with unknown biology [n = 4]), were assigned eight cycles. The 3-year overall survival was 81.4% ± 5.8%. Eight of nine deaths were in patients younger than 2 months of age at diagnosis (median, 9 days [range, 1 to 68 days]): five acute deaths were a result of hepatomegaly and associated toxicities; two were a result of late relapse in patients with unfavorable biology; and two were a result of treatment complications. No deaths occurred after protocol-mandated pre-emptive treatment of infants younger than 2 months with hepatomegaly, regardless of symptoms. A new scoring algorithm for emergent chemotherapy in patients with 4S disease was developed on the basis of this experience. CONCLUSION: The outcome for 4S neuroblastoma can be improved with pre-emptive chemotherapy for evolving hepatomegaly or other baseline comorbidities in infants younger than 2 months of age.
RCT Entities:
PURPOSE:Infants with stage 4S neuroblastoma usually have favorable outcomes with observation or minimal chemotherapy. However, young infants with symptoms secondary to massive hepatomegaly or with unfavorable tumor biology are at high risk of death. Our aim was to improve outcomes for patients with symptomatic and/or unfavorable biology 4S neuroblastoma with a uniform treatment approach using a biology- and response-based algorithm. PATIENTS AND METHODS: The subset of patients with 4S disease with MYCN-not amplified tumors with impaired or impending organ dysfunction, or with unfavorable histology and/or diploid DNA index, were eligible. Patients were assigned to receive two, four, or eight cycles of chemotherapy on the basis of histology, diploid DNA index, chromosome arm 1p or 11q loss of heterozygosity (LOH) status, and symptoms. RESULTS: Forty-nine eligible patients were enrolled: 41 were symptomatic and 28 had unfavorable biology. Seventeen patients (symptomatic, favorable biology) were assigned two cycles, 21 patients (any unfavorable biologic feature without 1p or 11q LOH) were assigned four cycles, and 11 patients (unfavorable biology including 1p and/or 11q LOH [n = 7] or symptomatic with unknown biology [n = 4]), were assigned eight cycles. The 3-year overall survival was 81.4% ± 5.8%. Eight of nine deaths were in patients younger than 2 months of age at diagnosis (median, 9 days [range, 1 to 68 days]): five acute deaths were a result of hepatomegaly and associated toxicities; two were a result of late relapse in patients with unfavorable biology; and two were a result of treatment complications. No deaths occurred after protocol-mandated pre-emptive treatment of infants younger than 2 months with hepatomegaly, regardless of symptoms. A new scoring algorithm for emergent chemotherapy in patients with 4S disease was developed on the basis of this experience. CONCLUSION: The outcome for 4S neuroblastoma can be improved with pre-emptive chemotherapy for evolving hepatomegaly or other baseline comorbidities in infants younger than 2 months of age.
Authors: Edward F Attiyeh; Wendy B London; Yael P Mossé; Qun Wang; Cynthia Winter; Deepa Khazi; Patrick W McGrady; Robert C Seeger; A Thomas Look; Hiroyuki Shimada; Garrett M Brodeur; Susan L Cohn; Katherine K Matthay; John M Maris Journal: N Engl J Med Date: 2005-11-24 Impact factor: 91.245
Authors: Denah R Taggart; Wendy B London; Mary Lou Schmidt; Steven G DuBois; Tom F Monclair; Akira Nakagawara; Bruno De Bernardi; Peter F Ambros; Andrew D J Pearson; Susan L Cohn; Katherine K Matthay Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: G Schleiermacher; J Michon; A Ribeiro; G Pierron; V Mosseri; H Rubie; C Munzer; J Bénard; N Auger; V Combaret; I Janoueix-Lerosey; A Pearson; D A Tweddle; N Bown; M Gerrard; K Wheeler; R Noguera; E Villamon; A Cañete; V Castel; B Marques; A de Lacerda; G P Tonini; K Mazzocco; R Defferrari; B de Bernardi; A di Cataldo; N van Roy; B Brichard; R Ladenstein; I Ambros; P Ambros; K Beiske; O Delattre; J Couturier Journal: Br J Cancer Date: 2011-11-10 Impact factor: 7.640
Authors: R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith Journal: Br J Cancer Date: 1977-01 Impact factor: 7.640
Authors: Elizabeth Sokol; Ami V Desai; Mark A Applebaum; Dominique Valteau-Couanet; Julie R Park; Andrew D J Pearson; Gudrun Schleiermacher; Meredith S Irwin; Michael Hogarty; Arlene Naranjo; Samuel Volchenboum; Susan L Cohn; Wendy B London Journal: J Clin Oncol Date: 2020-04-21 Impact factor: 44.544
Authors: Stefano Avanzini; Isabella Buffoni; Anna Rita Gigliotti; Stefano Parodi; Irene Paraboschi; Alessandro Inserra; Patrizia Dall'Igna; Anna Maria Fagnani; Giuseppe Martucciello; Mario Lima; Umberto Caccioppoli; Alberto Garaventa; Massimo Conte; Claudio Granata; Angela Rita Sementa; Elisa Tirtei; Giovanni Erminio; Bruno De Bernardi Journal: Pediatr Surg Int Date: 2020-10-29 Impact factor: 1.827
Authors: Clare J Twist; Mary Lou Schmidt; Arlene Naranjo; Wendy B London; Sheena C Tenney; Araz Marachelian; Hiroyuki Shimada; Margaret H Collins; Natia Esiashvili; E Stanton Adkins; Peter Mattei; Michael Handler; Howard Katzenstein; Edward Attiyeh; Michael D Hogarty; Julie Gastier-Foster; Elizabeth Wagner; Katherine K Matthay; Julie R Park; John M Maris; Susan L Cohn Journal: J Clin Oncol Date: 2019-08-06 Impact factor: 44.544
Authors: Asuka Kawano; Florette K Hazard; Bill Chiu; Arlene Naranjo; Brian LaBarre; Wendy B London; Michael D Hogarty; Susan L Cohn; John M Maris; Julie R Park; Julie M Gastier-Foster; Naohiko Ikegaki; Hiroyuki Shimada Journal: Am J Surg Pathol Date: 2021-08-01 Impact factor: 6.298
Authors: Inge M Ambros; Gian-Paolo Tonini; Ulrike Pötschger; Nicole Gross; Véronique Mosseri; Klaus Beiske; Ana P Berbegall; Jean Bénard; Nick Bown; Huib Caron; Valérie Combaret; Jerome Couturier; Raffaella Defferrari; Olivier Delattre; Marta Jeison; Per Kogner; John Lunec; Barbara Marques; Tommy Martinsson; Katia Mazzocco; Rosa Noguera; Gudrun Schleiermacher; Alexander Valent; Nadine Van Roy; Eva Villamon; Dasa Janousek; Ingrid Pribill; Evgenia Glogova; Edward F Attiyeh; Michael D Hogarty; Tom F Monclair; Keith Holmes; Dominique Valteau-Couanet; Victoria Castel; Deborah A Tweddle; Julie R Park; Sue Cohn; Ruth Ladenstein; Maja Beck-Popovic; Bruno De Bernardi; Jean Michon; Andrew D J Pearson; Peter F Ambros Journal: J Clin Oncol Date: 2020-09-09 Impact factor: 44.544
Authors: Meredith S Irwin; Arlene Naranjo; Fan F Zhang; Susan L Cohn; Wendy B London; Julie M Gastier-Foster; Nilsa C Ramirez; Ruthann Pfau; Shalini Reshmi; Elizabeth Wagner; Jed Nuchtern; Shahab Asgharzadeh; Hiroyuki Shimada; John M Maris; Rochelle Bagatell; Julie R Park; Michael D Hogarty Journal: J Clin Oncol Date: 2021-07-28 Impact factor: 50.717
Authors: Skye Balyasny; Sang Mee Lee; Ami V Desai; Samuel L Volchenboum; Arlene Naranjo; Julie R Park; Wendy B London; Susan L Cohn; Mark A Applebaum Journal: JAMA Netw Open Date: 2021-07-01